<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        14-5287-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CYTARABINE 100MG-1ML VIAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CYTARABINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        18
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        302.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Zydus Hospira Oncology Private Limited ZHOPL " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Zydus Hospira Oncology Private Limited ZHOPL 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2657]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Pfizer Saudi Trading
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            HOSPIRA UK LIMITED
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01BC01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Cytarabine Injection is an anti-cancer medicine. Treatment with an anti-cancer medicine is sometimes called cancer chemotherapy.<br />&nbsp;</p><p>Cytarabine Injection is used to treat some types of leukaemia (cancer affecting the blood) and lymphomas (cancer of the lymph glands). It may be used in combination with other anti-cancer medicines.</p><p>&nbsp;</p><p>You must talk to a doctor if you do not feel better or if you feel worse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Cytarabine Injection </strong>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to cytarabine or any of the other ingredients of this medicine (listed in section 6)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;if your blood cell count (number of cells in your blood) is very low due to some cause other than cancer (unless your doctor decides the benefits of treatment outweigh the risks)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;if you have had severe effects on your brain (encephalopathy) after radiation treatment or treatment with another anticancer medicine such as methotrexate</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;if you are pregnant (unless your doctor considers the benefits to the mother outweigh the risks to the unborn child)</p><p>&nbsp;</p><p>Tell your doctor if you think any of the above applies to you before this medicine is used.<br />&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>&nbsp;</p><p>Talk to your doctor or pharmacist before taking Cytarabine Injection</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Take special care with Cytarabine Injection </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if your blood cell count is low&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have any problems with your liver including jaundice (causes yellowing of the skin)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have recently received cancer medicine treatment or radiotherapy&nbsp; or if you are due to have radiotherapy (the side effects of radiotherapy can be made worse by cytarabine treatment)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cytarabine strongly reduces blood cell production in the bone marrow and your blood cell numbers can continue to fall for up to a week after stopping treatment. Your doctor will test your blood regularly and examine your bone marrow if required</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if your bone marrow is still recovering from the effects of other medicines (your doctor will only consider treatment with cytarabine if absolutely necessary)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serious and sometimes life-threatening side effects can occur in the central nervous system, the bowels, the lungs or the heart especially when treated with high doses of cytarabine</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the levels of uric acid (showing that the cancer cells are destroyed) in your blood (hyperuricemia) may be high during treatment. Your doctor will tell you if you need to take any medicine to control this</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; during treatment with cytarabine administration of certain vaccines is not advised. If required, consult your doctor</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; during treatment with cytarabine, granulocyte transfusion should be avoided as severe breathing problems have been reported. Your doctor will determine if this treatment is required</p><p>&nbsp;</p><p>Tell your doctor if either of the above applies to you before this medicine is used. Your doctor will monitor your blood to check your blood cell count, your liver and kidney functions and to monitor for raised uric acid levels.<br />&nbsp;</p><p>Special care will be taken if cytarabine is to be given to a child. Cytarabine should not be used in infants.</p><p>&nbsp;</p><p><strong>Other medicines and Cytarabine Injection</strong></p><p>Tell your doctor if you are using, have recently used or might use any other medicines. Special care is needed if you are taking/using other medicines as some could interact with cytarabine.<br />&nbsp;</p><p>The effectiveness of the following medicines may be reduced or increased by cytarabine:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; digoxin or beta-acetyl digoxin tablets (heart medicine)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gentamicin (an antibiotic)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5-fluorocytosine (a medicine used to treat fungal infections)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other medicines which decrease the activity of the immune system</p><p>&nbsp;</p><p>&nbsp;<strong>Pregnancy, breast-feeding and fertility </strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine</p><p>Avoid becoming pregnant while you or your partner is being treated with cytarabine. As there is a risk of birth defects, women of childbearing potential or their partner should use appropriate contraception methods during and up to 6 months after treatment with cytarabine to prevent pregnancy.<br />&nbsp;</p><p>You should stop breast-feeding before starting treatment with cytarabine because this medicine may be harmful to infants being breast-fed.<br />&nbsp;</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines </strong></p><p>&nbsp;</p><p>Do not drive or use machines if you experience any side effect which may lessen your ability to do so.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.</p><p>This medicine may be given by injection (using a syringe) under the skin (subcutaneous) or into a vein (intravenous). It may also be given by infusion (drip) into a vein. If given as an infusion, Cytarabine Injection will be diluted first.<br />&nbsp;</p><p>Cytarabine 100 mg/ml Injection must <strong>not </strong>be injected intrathecally (into the spine).<br />&nbsp;</p><p><strong>Recommended Dose </strong></p><p>&nbsp;</p><p>Your doctor will work out the correct dose of cytarabine for you and how often it must be given.<br />&nbsp;</p><p>The dose will depend on your medical condition, your size and how well your liver is working. Your doctor will tell how well your liver is working using blood tests.<br />&nbsp;</p><p>You will have regular blood tests after your dose of cytarabine to check for side effects. These tests may be done more often if you are elderly, as you may be more likely to get side effects. Treatment may have to be stopped if your blood cell count drops too low.<br />&nbsp;</p><p><strong>If you use more Cytarabine Injection than you should</strong></p><p>This medicine will be given to you in a hospital, under the supervision of a doctor. It is unlikely that you will be given too much or too little, however, tell your doctor or nurse if you have any concerns.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>If any of the following happen, tell your doctor or nursing staff immediately: </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sore mouth, particularly if you have a number of ulcers inside of the mouth</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe allergic reaction - you may experience a sudden itchy rash (hives), swelling of the hands, feet, ankles, face, lips, mouth or throat (which may cause difficulty in swallowing or breathing), and you may feel you are going to faint</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; symptoms of an infection, e.g. fever, chills, aches or soreness when swallowing</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unexpected bleeding e.g. bleeding gums, blood in urine or vomit, unexpected bruises</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; black tarry stools which may indicate bleeding in the digestive system</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe pain in the chest and difficulty breathing (this maybe a symptom of pericarditis)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe pain in the abdomen (this may be a symptom of inflammation of the pancreas)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of vision, loss of sense of touch, mental disturbance or loss of ability to move normally (this medicine may cause side effects to the brain and eyes which are usually reversible but may be very serious)</p><p>&nbsp;</p><p>These are serious side effects. You may need urgent medical attention.<br />&nbsp;</p><p><strong>If you experience any of the following tell your doctor as soon as possible:</strong><br />&nbsp;</p><p>The side effects of cytarabine are dependent on the dose. The digestive tract is most commonly affected, but also the blood.</p><p><br />&nbsp;<strong>Common: may affect up to 1 in 10 people</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in cells responsible for providing immunity, carrying oxygen around the body and for normal blood clotting shown as a reduction in the amount of red and white cells and platelets in the blood or abnormal red blood cells, anaemia, shortness of breath, unexpected bleeding e.g. bleeding gums, blood in urine or vomit, unexpected bruises</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high levels of uric acid in your blood due to the breakdown of cancer cells during treatment with cytarabine (your doctor will monitor for this)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced consciousness, speaking difficulties, abnormal eye movements (nystagmus)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reversible effects on the eyes such as sore eyes with bleeding (haemorrhagic conjunctivitis), vision disturbance, sensitivity to light (photophobia), watery or burning eyes and inflammation of the surface of the eye (cornea) (keratitis)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling or being sick, diarrhoea, sores or ulcers in the mouth or anus (back passage), mild pain in the abdomen</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reversible effects on the liver such as increased enzyme levels</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reversible effects to the skin such as reddening (erythema), blistering, rash, hives, blood vessel inflammation (vasculitis)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hair loss</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; impaired / disturbed kidney function, problems passing urine</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood clots causing inflammation at the site of injection</p><p>&nbsp;</p><p><strong>Uncommon: may affect up to 1 in 100 people</strong></p><p>&bull; whole body infection (sepsis) seen as a fever, vomiting, confusion, dizziness, chills</p><p>&bull; lung infection</p><p>&bull; headache</p><p>&bull; numbness or weakness of the arms and legs, paralysis of the legs and lower body when cytarabine is given into the space surrounding the spinal cord (intrathecal)</p><p>&bull; inflammation of the sac that surrounds the heart</p><p>&bull; shortness of breath</p><p>&bull; sore throat</p><p>&bull; inflammation of the food pipe (oesophagus), ulcers in the food pipe</p><p>&bull; bowel cysts, severe bowel inflammation, serious infection of the membrane that lines the abdomen (peritonitis)</p><p>&bull; brown/black spots on the skin (lentigo), ulceration of the skin, itching</p><p>&bull; painful redness and blistering on the hands and the soles of the feet</p><p>&bull; joint and muscle pain</p><p>&bull; inflammation at the site of injection</p><p>&nbsp;</p><p><strong>Very rare: may affect up to 1 in 10,000 people</strong></p><p>&bull; irregular heart beat (arrhythmia)</p><p>&bull; redness and itchy bumps on hands or legs, associated with inflammation of the sweat glands</p><p>&nbsp;</p><p><strong>Not known: frequency cannot be estimated from the available data</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low counts of pre-stages of red cells in the blood (reticulocytopenia)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness, inflammation of a nerve or part of the nervous system, damage to nerve tissues and pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sore or itchy eyes</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; black tarry stools which may indicate bleeding in the digestive system</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; impaired liver function</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yellowing of the skin or yellowing of the whites of the eyes (jaundice)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash, pigmented spots on the skin (freckles), skin bleeding</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidneys may not work properly</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lack of periods and low sperm count (amenorrhoea and azoospermia)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irritation or infection at the site of injection</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding of the lining of the mouth</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; slower heartbeat</p><p>&nbsp;</p><p>The side effects on the digestive tract are less if cytarabine is given by infusion rather than by bolus injection. Your doctor may prescribe local steroids (anti-inflammatory medicines) to reduce effects on the eyes such as sore eyes with bleeding (haemorrhagic conjunctivitis).<br />&nbsp;</p><p>Cytarabine may lead to changes in your blood cells. Your doctor will take blood samples to monitor for these and also to check how well your liver and kidneys are working.<br />&nbsp;</p><p>Sometimes the following side effects can occur together, usually 6-12 hours after receiving cytarabine:<br />&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling generally unwell with a high temperature</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in bone, muscle and occasionally the chest</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sore eyes</p><p>&nbsp;</p><p>This is known as &lsquo;cytarabine syndrome&rsquo; and it can be treated. If you experience these side effects please tell your doctor or nurse as soon as possible.<br />&nbsp;</p><p>Side effects after high dose cytarabine treatment:</p><p>Severe and at times fatal side effects on the blood, eyes, lungs, nervous system, liver, digestive or genital system have been reported after using experimental dose schedules. The side effects have included severe bone marrow suppression, reversible effects on the cornea (surface of the eye), effects on the brain (usually reversible), drowsiness and convulsion, ulcers in the digestive system which may lead to infection of your abdominal lining (peritonitis), inflammation of the pancreas, liver abscess or enlargement, blood clots in the vein in the liver, blood infection, fluid in the lungs, absence of menstrual periods in women or complete lack of sperm in the ejaculate in men, heart muscle disease or abnormal muscle breakdown, which may lead to kidney problems (rhabdomyolysis).<br />&nbsp;</p><p><strong>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor. </strong></p><p><strong>&nbsp;</strong></p><p><strong><u>Reporting of side effects</u></strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.</p><p>&nbsp;</p><p>You can also report side effects directly via the national reporting system. By reporting side effects you can help provide more information on the safety of this medicine.</p><p><strong>To Report side effects</strong></p><ul><li>Saudi Arabia</li></ul><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre ( NPC )</p><ul><li>SFDA Call center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: www.sfda.gov.sa/npc https://ade.sfda.gov.sa/</li></ul></td></tr></tbody></table><p><br /><strong>&nbsp;Other GCC States:</strong></p><p> Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the reach and sight of children</p><p><strong>Expiry </strong></p><p>Do not use Cytarabine after the expiry date which is stated on the carton label&nbsp; after EXP. The expiry date refers to the last day of that month.</p><p><br /><strong>Storage </strong></p><p>The vial should be kept in the outer carton, in order to protect from light. Do not store above 25&deg;C.</p><p>&nbsp;</p><p>Do not refrigerate or freeze. Discard any unused contents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is cytarabine. Each millilitre (ml) of solution contains 100 milligrams (mg) of cytarabine.<br />&nbsp;</p><p>The other ingredients are Water for Injections, Hydrochloric Acid and Sodium Hydroxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Cytarabine Injection is a clear, colourless solution for injection which comes in glass containers called vials. 

It may be supplied in packs containing: 
 
• 5 x 500 mg/5 ml vials 
• 1 x 1000 mg/10 ml vials 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Marketing authorisation holder:</strong></p><p>Hospira UK Limited, Horizon, Honey Lane, Hurley, Maidenhead, SL6 6RJ, United Kingdom<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                October 2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">حقن سيتارابين هي دواء مضاد للسرطان. أحيانًا ما يعرف العلاج بدواء مضاد للسرطان بالعلاج الكيميائي للسرطان.<br />&nbsp;</p><p dir="RTL">تستخدم حقن سيتارابين لعلاج بعض أنواع اللوكيميا (سرطان يصيب الدم) والليمفوما (سرطان الغدد الليمفاوية). ويمكن استخدامها بالتزامن مع أدوية أخرى مضادة للسرطان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أن تستشير طبيبك إذا كنت لا تشعر بتحسن أو كنت تشعر بتفاقم حالتك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع استعمال حقن سيتارابين </strong>&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الحساسية تجاه سيتارابين أو تجاه أي مكون آخر من مكونات هذا الدواء (المدرجة في القسم ٦)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كان تعداد خلايا دمك (عدد الخلايا في دمك) قليل جدًا نتيجة لسبب آخر غير السرطان (ما لم يقرر طبيبك أن فوائد العلاج تفوق مخاطره)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كان قد سبق لك الإصابة بآثار شديدة بمخك (اعتلال الدماغ) بعد العلاج الإشعاعي أو العلاج بدواء آخر مضاد للسرطان مثل ميثوتريكسات</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كنتِ حاملًا (إلا إذا كان طبيبكِ يرى أن فوائد العلاج للأم تفوق مخاطره على الجنين)</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك إذا كنت تعتقد أن أيًا من الحالات المذكورة أعلاه تنطبق عليك قبل أن يتم استخدام هذا الدواء.<br />&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال حقن سيتارابين</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">استشر طبيبك أو الصيدلي قبل أخذ حقن سيتارابين</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>توخ الحذر بشكل خاص مع حقن سيتارابين </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان تعداد خلايا دمك منخفضًا&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أي مشكلات في كبدك بما في ذلك اليرقان (يسبب اصفرار الجلد)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد تلقيت مؤخرًا علاجًا بدواء مضاد للسرطان أو علاجًا إشعاعيًا أو إذا كان يفترض بك تلقي علاج إشعاعي (يمكن أن تصبح الآثار الجانبية للعلاج الإشعاعي أسوأ مع العلاج بسيتارابين)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يقلل سيتارابين بشدة من إنتاج خلايا الدم في نخاع العظم، ويمكن أن تستمر أعداد خلايا دمك في الانخفاض لفترة تصل إلى أسبوع بعد إيقاف العلاج. سوف يختبر طبيبك دمك بانتظام ويفحص نخاع عظمك إذا لزم الأمر</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان نخاع عظمك لا يزال يتعافى من آثار الأدوية الأخرى (فسوف يأخذ طبيبك العلاج بسيتارابين في عين الاعتبار فقط إذا كان ضروريًا للغاية)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن أن تحدث آثار جانبية خطيرة وأحيانًا مهددة للحياة في الجهاز العصبي المركزي أو الأمعاء أو الرئتين أو القلب خاصة عند العلاج بجرعات عالية من سيتارابين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تكون مستويات حمض اليوريك (التي تظهر أن الخلايا السرطانية تم تدميرها) في دمك مرتفعة (فرط حمض اليوريك في الدم) أثناء العلاج. سوف يخبرك طبيبك إذا كنت تحتاج إلى تناول أي دواء للتحكم في هذا</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينصح باستعمال لقاحات معينة أثناء العلاج بسيتارابين. إذا كان ذلك ضروريًا، فاستشر طبيبك</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أثناء العلاج بسيتارابين، ينبغي تجنب نقل الخلايا المحببة حيث إنه قد تم الإبلاغ عن حدوث مشكلات شديدة في التنفس. سيحدد طبيبك ما إذا كان هذا العلاج مطلوبًا</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك قبل استخدام هذا الدواء إذا كان أي من الحالات المذكورة أعلاه تنطبق عليك. سوف يراقب طبيبك دمك لتفقد تعداد خلايا دمك ووظائف كبدك وكليتيك ولرصد أي ارتفاع في مستويات حمض اليوريك.<br />&nbsp;</p><p dir="RTL">سيتم توخي الحذر بشكل خاص في حالة إعطاء سيتارابين لطفل. ينبغي عدم استخدام سيتارابين مع الرضع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التداخلات الدوائية من أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">&nbsp;أخبر طبيبك إذا كنت تستخدم أو استخدمت مؤخرًا أو قد تستخدم أي أدوية أخرى. يلزم إعمال الحذر الخاص إذا كنت تتناول/تستخدم أدوية أخرى حيث إن بعضها يمكن أن يتفاعل مع سيتارابين.<br />&nbsp;</p><p dir="RTL">يمكن أن تنخفض فعالية الأدوية التالية أو تزداد مع استعمال سيتارابين:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أقراص ديجوكسين أو بيتا-أسيتيل ديجوكسين (دواء للقلب)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جنتاميسين (مضاد حيوي)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ٥-فلوروسيتوسين (دواء يستخدم لعلاج العدوى الفطرية)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الأخرى التي تقلل من نشاط الجهاز المناعي</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة </strong></p><p dir="RTL">إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية أو تعتقدين أنكِ قد تكونين حاملًا أو تخططين للإنجاب، فاطلبي النصيحة من طبيبكِ أو الصيدلي قبل أخذك لهذا الدواء</p><p dir="RTL">تجنبي الحمل أثناء خضوعكِ أو خضوع زوجكِ للعلاج باستخدام سيتارابين. نظرًا لأن هناك خطر للإصابة بعيوب ولادية، ينبغي على السيدات القادرات على الإنجاب أو أزواجهن استخدام وسائل ملائمة لمنع الحمل أثناء العلاج بسيتارابين ولمدة تصل إلى ٦ أشهر بعد انتهائه لمنع حدوث حمل.</p><p dir="RTL">ينبغي عليكِ إيقاف الرضاعة الطبيعية قبل بدء العلاج بسيتارابين لأن هذا الدواء يمكن أن يكون مضرًا بالمواليد الذين يرضعون رضاعة طبيعية.<br />&nbsp;</p><p dir="RTL">استشيري طبيبكِ أو الصيدلي قبل تناول أي دواء.</p><p dir="RTL"><strong>تأثير حقن سيتارابين على القيادة واستخدام الآلات</strong></p><p dir="RTL">لا تقم بالقيادة أو استخدام الآلات إذا أصبت بأي آثار جانبية قد تحد من قدرتك على فعل ذلك.<br />&nbsp;</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات حقن سيتارابين</strong></p><p dir="RTL"><strong>تحتوي حقن سيتارابين على الصوديوم</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي حقن سيتارابين ۱۰۰ ملجم/مل على أقل من واحد مليمول من الصوديوم (۲۳ ملجم) لكل قارورة، أي أنه يُعد &quot;خاليًا من الصوديوم&quot; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قم دائمًا باستخدام هذا الدواء تمامًا كما أخبرك طبيبك. تحقق مع طبيبك إذا لم تكن متأكدًا مما يجب عليك فعله.</p><p dir="RTL">يمكن إعطاء هذا الدواء بواسطة الحقن (باستخدام محقنة) تحت الجلد أو داخل أحد الأوردة (الحقن عن طريق الوريد). يمكن أيضًا أن يتم إعطاؤه عن طريق التسريب (التقطير) داخل أحد الأوردة. إذا تم إعطاؤه على هيئة تسريب، فسيتم تخفيف حقن سيتارابين أولًا.<br />&nbsp;</p><p dir="RTL">يجب <strong>عدم </strong>حقن سيتارابين ۱۰۰ ملجم/مل داخل القراب (داخل الحبل الشوكي).</p><p dir="RTL"><strong>الجرعة الموصى بها</strong></p><p dir="RTL">سوف يحسب طبيبك الجرعة الصحيحة الملائمة لك من سيتارابين والمعدل الذي يجب أن يتم إعطاؤها به.<br />&nbsp;</p><p dir="RTL">وسيعتمد مقدار الجرعة على حالتك الطبية وحجمك ومدى كفاءة عمل كبدك. سوف يعرف طبيبك الكفاءة التي يعمل بها كبدك باستخدام فحوصات الدم.<br />&nbsp;</p><p dir="RTL">سوف تخضع لفحوصات دم منتظمة بعد إعطائك جرعتك من سيتارابين للتحقق في حالة حدوث آثار جانبية. قد يتم إجراء هذه الفحوصات بمعدل أكثر تكرارًا إذا كنت مسنًا، حيث إنك يمكن أن تكون أكثر عرضة للإصابة بالآثار الجانبية. قد يلزم إيقاف العلاج إذا انخفض تعداد خلايا دمك بدرجة كبيرة للغاية.<br />&nbsp;</p><p dir="RTL"><strong>الجرعة الزائدة من حقن سيتارابين</strong></p><p>سوف يُعطى لك هذا الدواء في مستشفى تحت إشراف طبيب. ومن غير المرجح أن يتم إعطاؤك كمية أكبر أو أقل بكثير مما ينبغي، ومع ذلك، أخبر طبيبك أو الممرضة إذا كانت لديك أي مخاوف.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، إلا أنها لا تصيب الجميع.</p><p dir="RTL"><strong>إذا حدث أي مما يلي، فأخبر طبيبك أو طاقم التمريض فورًا: </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الفم، خصوصًا إذا كان لديك عدد من القرح داخل الفم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تفاعل الحساسية الشديد - يمكن أن تصاب بطفح جلدي مفاجئ مثير للحكة، وتورم في اليدين أو القدمين أو الكاحلين أو الوجه أو الشفتين أو الفم أو الحلق (ما يمكن أن يسبب صعوبة في البلع أو التنفس)، وقد تشعر بأنك على وشك الإصابة بالإغماء </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض الإصابة بعدوى، مثل الحمى أو القشعريرة أو الأوجاع أو الألم عند البلع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النزيف غير المتوقع، على سبيل المثال نزيف اللثة، وجود دم في البول أو القيء، الكدمات غير المتوقعة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البراز القطراني الأسود، والذي قد يكون مؤشرًا على وجود نزيف في الجهاز الهضمي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الألم الشديد في الصدر وصعوبة التنفس (قد يكون هذا عرضًا لالتهاب الغشاء المحيط بالقلب)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الألم الشديد في البطن (قد يكون هذا عرضًا لالتهاب البنكرياس)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الرؤية، فقدان حاسة اللمس، الاضطراب العقلي أو فقدان القدرة على التحرك بشكل طبيعي (يمكن أن يسبب هذا الدواء آثارًا جانبية بالمخ والعينين عادة ما تكون قابلة للعكس ولكنها يمكن أن تكون خطيرة للغاية)</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن هذه آثار جانبية خطيرة. وقد تحتاج إلى رعاية طبية طارئة.<br />&nbsp;</p><p dir="RTL"><strong>إذا أصبت بأي مما يلي، فأخبر طبيبك في أقرب وقت ممكن:</strong><br />&nbsp;</p><p dir="RTL">تعتمد الآثار الجانبية لسيتارابين على الجرعة. الجهاز الهضمي هو الأكثر تأثرًا عادة، ولكن الدم يتأثر أيضًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة: قد تصيب ما يصل إلى شخص واحد بين كل </strong>۱۰<strong> أشخاص</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد الخلايا المسؤولة عن منح الجسم المناعة والخلايا المسؤولة عن نقل الأكسجين إلى أنحاء الجسم والخلايا الضرورية لتجلط الدم بصورة طبيعية يظهر على هيئة انخفاض في عدد خلايا الدم الحمراء والبيضاء والصفيحات الدموية في الدم أو خلايا الدم الحمراء غير الطبيعية، فقر الدم، ضيق التنفس، النزيف غير المتوقع مثل نزيف اللثة، وجود دم في البول أو القيء، الكدمات غير المتوقعة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات حمض اليوريك في دمك نتيجة لتكسر الخلايا السرطانية أثناء العلاج بسيتارابين (سوف يراقب طبيبك هذا)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الوعي، صعوبات التحدث، الحركة غير الطبيعية في العين (الرأرأة)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آثار على العين قابلة للعكس مثل التهاب العينين المصحوب بالنزيف (التهاب الملتحمة النزفي)، اضطراب الرؤية، الحساسية تجاه الضوء (رهاب الضوء)، إدماع أو حرقة العينين والتهاب سطح العين (القرنية) (التهاب القرنية)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالرغبة في التقيؤ أو التقيؤ بالفعل، الإسهال، التهابات أو تقرحات في الفم أو الشرج، ألم خفيف في البطن</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آثار على الكبد قابلة للعكس مثل زيادة مستويات الإنزيمات</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آثار على الجلد قابلة للعكس مثل الاحمرار (البقع الحمراء)، البثور، الطفح الجلدي، التهاب الأوعية الدموية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل/اضطراب وظائف الكلى، مشكلات في التبول</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلطات دموية تسبب الالتهاب في موضع الحقن</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة: قد تصيب ما يصل إلى شخص واحد بين كل </strong>۱۰۰<strong> شخص</strong></p><p dir="RTL">&bull; عدوى الجسم كله (الإنتان) التي تظهر على هيئة حمى، قيء، ارتباك، دوار، قشعريرة</p><p dir="RTL">&bull; عدوى بالرئة</p><p dir="RTL">&bull; صداع</p><p dir="RTL">&bull; خدر أو ضعف في الذراعين والساقين، شلل الساقين والجزء السفلي من الجسم عند إعطاء سيتارابين في داخل الفراغ المحيط بالحبل الشوكي (داخل القراب)</p><p dir="RTL">&bull; التهاب الغشاء المحيط بالقلب</p><p dir="RTL">&bull; ضيق التنفس</p><p dir="RTL">&bull; التهاب الحلق</p><p dir="RTL">&bull; التهاب المريء، تقرحات المريء</p><p dir="RTL">&bull; تكيسات الأمعاء، التهاب الأمعاء الشديد، عدوى خطيرة في الغشاء الذي يبطن البطن (التهاب الصفاق)</p><p dir="RTL">&bull; بقع بنية/سوداء على الجلد (النمشة)، تقرح الجلد، الحكة</p><p dir="RTL">&bull; احمرار وبثور مؤلمة على اليدين وباطن القدمين</p><p dir="RTL">&bull; ألم المفاصل والعضلات</p><p dir="RTL">&bull; التهاب في موضع الحقن</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة للغاية: قد تصيب ما يصل إلى شخص واحد بين كل </strong>۱۰۰۰۰<strong> شخص</strong></p><p dir="RTL">&bull; عدم انتظام ضربات القلب (اضطراب نظم القلب)</p><p dir="RTL">&bull; احمرار ونتوءات مثيرة للحكة على اليدين أو القدمين مرتبطة بالتهاب الغدد العرقية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروفة: لا يمكن تقدير معدل التكرار من البيانات المتاحة </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض تعداد خلايا الدم الحمراء غير الناضجة في الدم (نقص الخلايا الشبكية)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوار، التهاب عصب أو جزء من الجهاز العصبي، تلف النسيج العصبي والألم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب العينين أو الشعور بحكة بهما</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البراز القطراني الأسود، والذي قد يكون مؤشرًا على وجود نزيف في الجهاز الهضمي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل وظائف الكبد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد أو بياض العينين (اليرقان)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي، بقع صبغية على الجلد (نمش)، نزيف الجلد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد لا تعمل الكليتان كما ينبغي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انعدام الدورات الحيضية وانخفاض تعداد الحيوانات المنوية (انقطاع الحيض وفقد النطاف)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الصدر</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تهيج أو التهاب في موضع الحقن</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف في بطانة الفم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضربات قلب أبطأ</p><p dir="RTL">&nbsp;</p><p dir="RTL">تكون الآثار الجانبية على الجهاز الهضمي أخف وطأة إذا تم إعطاء سيتارابين عن طريق التسريب بدلًا من الحقن دفعة واحدة. قد يصف طبيبك الستيرويدات الموضعية (أدوية مضادة للالتهاب) لتقليل الآثار على العينين مثل التهاب العينين المصحوب بنزيف (التهاب الملتحمة النزفي).<br />&nbsp;</p><p dir="RTL">يمكن أن يؤدي سيتارابين إلى حدوث تغيرات في خلايا دمك. سوف يسحب طبيبك عينات دم لرصد هذه التغيرات وأيضًا لتفقد الكفاءة التي يعمل بها كبدك وكليتاك.<br />&nbsp;</p><p dir="RTL">أحيانًا يمكن أن تحدث الآثار الجانبية التالية معًا، عادة بعد ٦-۱۲ ساعة من تلقي سيتارابين:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتوعك العام مع ارتفاع درجة الحرارة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بألم في العظام والعضلات وأحيانًا في الصدر</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب العينين</p><p dir="RTL">&nbsp;</p><p dir="RTL">تعرف هذه الأعراض بـ&quot;متلازمة سيتارابين&quot; ويمكن علاجها. إذا أصبت بهذه الآثار الجانبية، يرجى إخبار طبيبك أو الممرضة في أقرب وقت ممكن.<br />&nbsp;</p><p dir="RTL">الآثار الجانبية التالية لتناول جرعة عالية من العلاج بسيتارابين:</p><p dir="RTL">تم الإبلاغ عن آثار جانبية شديدة ومميتة أحيانًا على الدم أو العينين أو الرئتين أو الجهاز العصبي أو الكبد أو الجهاز الهضمي أو التناسلي بعد استخدام جداول الجرعات التجريبية. تضمنت الآثار الجانبية تثبيط شديد لنخاع العظم أو آثار على القرنية (سطح العين) قابلة للعكس أو آثار على المخ (عادة ما تكون قابلة للعكس) أو نعاس وتشنج أو قرح في الجهاز الهضمي قد تؤدي إلى عدوى في البطانة الداخلية للبطن (التهاب الصفاق) أو التهاب البنكرياس أو خراج بالكبد أو تضخم الكبد أو جلطات دموية في وريد بالكبد أو عدوى الدم أو سوائل في الرئتين أو انقطاع الدورة الشهرية لدى السيدات أو انعدام تام للحيوانات المنوية عند القذف لدى الرجال أو مرض عضلة القلب أو انحلال غير طبيعي في العضلات قد يؤدي بدوره إلى مشكلات بالكلى (انحلال الربيدات).<br />&nbsp;</p><p dir="RTL"><strong>إذا ما تفاقمت شدة أي من الآثار الجانبية بشكل خطير أو لاحظت ظهور آثار جانبية غير واردة في هذه النشرة، يرجى إخبار طبيبك. </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية </strong></p><p dir="RTL"><strong>إذا أصبت بأي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي أو الممرض. يتضمن هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة.</strong></p><p dir="RTL"><strong>يمكنك أيضًا الإبلاغ عن الآثار الجانبية مباشرةً عبر نظام الابلاغ القومي. بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</strong></p><ul><li dir="RTL">المملكة العربية السعودية</li></ul><p dir="RTL"><em>&nbsp;</em></p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><ul><li dir="RTL">الرقم الموحد: ۱٩٩٩٩</li><li dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</li><li dir="RTL">الموقع الإلكتروني: <u>https://ade.sfda.gov.sa</u></li></ul></td></tr></tbody></table><p dir="RTL"><br /><strong>دول الخليج الأخرى:</strong></p><p dir="RTL"><strong>&nbsp; </strong>الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احتفظ بهذا الدواء بعيدًا عن متناول ومرأى الأطفال</p><p dir="RTL"><strong>انتهاء الصلاحية </strong></p><p dir="RTL">لا تستخدم سيتارابين بعد تاريخ انتهاء الصلاحية المدون على ملصق العبوة الكرتونية بعد &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.</p><p dir="RTL"><br /><strong>التخزين </strong></p><p dir="RTL">ينبغي الاحتفاظ بالقارورة في العبوة الكرتونية الخارجية لحمايتها من الضوء، وينبغي تخزينها في درجة حرارة لا تزيد عن ۲٥ درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عدم حفظها في البراد (الثلاجة) أو تجميدها. تخلص من الكميات الغير مستخدمه.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي سيتارابين. يحتوي كل ملليلتر (مل) من المحلول على ۱۰۰ مليجرام (ملجم) من سيتارابين.</p><p dir="RTL">المكونات الأخرى هي ماء مخصص للحقن، وحمض هيدروكلوريك وهيدروكسيد الصوديوم.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">حقن سيتارابين هي محلول صاف عديم اللون للحقن يتم تزويده في حاويات زجاجية تدعى قوارير.<br />&nbsp;</p><p dir="RTL">يمكن توفير الدواء في عبوات تحتوي على:</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&bull; ٥ قوارير x ٥۰۰ ملجم/٥ مل</p><p dir="RTL">&bull; قارورة واحدة x ۱۰۰۰ ملجم/۱۰ مل</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">Hospira UK Limited, Horizon, Honey Lane, Hurley, Maidenhead, SL6 6RJ, United Kingdom، المملكة المتحدة<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أكتوبر/تشرين الأول ۲۰۲۰
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cytarabine 100 mg/ml Injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 1 ml contains 100 mg of cytarabine

Presentations: 500 mg/5ml and 1000 mg/10ml

For the full list of excipients see 6.1


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection.

Clear, colourless solution.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cytarabine may be used alone or in combination with other antineoplastic agents.&nbsp; It is indicated alone or in combination for induction of remission and/or maintenance in patients with acute myeloid leukaemia, acute non-lymphoblastic leukaemias, acute lymphoblastic leukaemias, acute lymphocytic leukaemia, erythroleukaemia, blast crises of chronic myeloid leukaemia, diffuse histiocytic lymphomas (non-Hodgkin&rsquo;s lymphomas of high malignancy), meningeal leukaemia and meningeal neoplasms.&nbsp; Clinicians should refer to the current literature on combination therapy before initiating treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p>Cytarabine Injection can be diluted with Sterile Water for Injections BP, Glucose Intravenous Infusion BP or Sodium Chloride Intravenous Infusion BP.&nbsp; Prepared infusions, in the recommended diluents, should be used immediately.&nbsp; Alternatively, the diluted infusion fluids may be stored at 2-8&deg;C, protected from light, but portions remaining unused after 24 hours must be discarded.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remission Induction:&nbsp; Adults</strong></p><p>&nbsp;</p><p><strong>Continuous Dosing:&nbsp; </strong>The usual dose in leukaemia is 2 mg/kg by rapid intravenous injection daily for ten days.&nbsp; If after ten days neither therapeutic response nor toxicity has been observed, the dose may be increased to 4 mg/kg until a therapeutic response or toxicity is evident.&nbsp; Daily blood counts should be taken.&nbsp; Almost all patients can be carried to toxicity with these doses.</p><p>&nbsp;</p><p>Alternatively, 0.5 to 1 mg/kg may be infused daily in 1-24 hours for ten days, and then at a rate of 2 mg/kg/day until toxicity is observed.&nbsp; Continue to toxicity or until remission occurs.&nbsp; Results from one hour infusions have been satisfactory in the majority of patients.</p><p>&nbsp;</p><p><strong>Intermittent dosing:&nbsp; </strong>Cytarabine may be given as intermittent intravenous doses of 3-5 mg/kg daily, for five consecutive days. &nbsp;This course of treatment can be repeated after an interval of 2 to 9 days and repeated until the therapeutic response or toxicity is exhibited.</p><p>&nbsp;</p><p>Evidence of bone marrow improvement has been reported to occur 7-64 days after the beginning of therapy.</p><p>&nbsp;</p><p>In general, if a patient shows neither remission nor toxicity after a trial period, then cautiously administered higher doses can be administered.&nbsp; Generally patients tolerate higher doses given by rapid intravenous injection rather than slow infusion.</p><p>&nbsp;</p><p>As a single agent for induction of remissions in patients with acute leukaemia, cytarabine has been given in doses of 200 mg/m<sup>2</sup> by continuous intravenous infusion for five days at approximately 2 week intervals.</p><p><strong>&nbsp;</strong></p><p><strong>Maintenance therapy:&nbsp; </strong>To maintain remission, doses of 1 mg/kg may be given intravenously or subcutaneously, once or twice weekly.</p><p>&nbsp;</p><p><strong>Leukemic Meningitis:&nbsp; </strong>Therapy for established meningitis employs a wide variety of dose regimens but a recommended total daily dose not exceeding 100 mg, alternating with methotrexate is recommended.</p><p>&nbsp;</p><p>Myelosuppression, anaemia and thrombocytopenia occur almost to all patients given daily infusions or injections.&nbsp; Myelosuppression is biphasic and nadirs at 7-9 and 15-24 days.&nbsp; Evidence of bone marrow improvement may be expected 7-64 (mean 28) days after the beginning of treatment.</p><p><strong>&nbsp;</strong></p><p><strong><u>Paediatric population:</u></strong><strong> </strong>Children appear to tolerate higher doses of cytarabine than adults, and where the range of doses is given, children should receive the higher dose.</p><p>&nbsp;</p><p><strong>Elderly:&nbsp; </strong>No data is available to suggest that a change in dose is necessary in the elderly.&nbsp; However, the elderly patient is more susceptible to toxic reactions and therefore particular attention should be paid to drug induced leukopenia, thrombocytopenia and anaemia.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Method of administration</u></p><p>&nbsp;</p><p>Cytarabine 100 mg/ml Injection is a ready to use injection and can be administered by the intravenous and subcutaneous routes.&nbsp; <strong>Cytarabine 100 mg/ml Injection should not be administered by the intrathecal route due to the slight hypertonicity of this formulation.&nbsp; (<u>See section 4.8</u>).</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to cytarabine or to any of the excipients listed in 6.1.  

Anaemia, leukopenia and thrombocytopenia of non-malignant aetiology (e.g. bone marrow aplasia), unless the benefits outweigh the risk. 

Degenerative and toxic encephalopathies, especially after the use of methotrexate or treatment with ionizing radiation. 

During pregnancy, cytarabine should only be administrated on strict indication, where the benefits of the drug to the mother should be weighed against possible hazards to the foetus. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cytarabine is a potent bone marrow suppressant.&nbsp; Therapy should be started cautiously in patients with pre-existing drug-induced bone marrow suppression. Patients receiving the drug should be kept under close medical supervision.&nbsp; Leucocyte and platelet counts should be performed frequently and daily during induction. Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood.&nbsp;</p><p>&nbsp;</p><p>Facilities should be available for management of complications, possibly fatal, of bone marrow suppression (infection resulting from granulocytopenia and other impaired body defences, and haemorrhage secondary to thrombocytopenia).</p><p>&nbsp;</p><p>One case of anaphylaxis that resulted in cardiopulmonary arrest and necessitated resuscitation has been reported.&nbsp; This occurred immediately after intravenous cytarabine was administered.</p><p>&nbsp;</p><p>Severe and at times fatal central nervous system (CNS), gastrointestinal (GI) and pulmonary toxicity (different from that seen with conventional therapy regimens of cytarabine) has been reported following some experimental cytarabine dose schedules.&nbsp; These reactions include reversible corneal toxicity; cerebral and cerebellar dysfunction, usually reversible; somnolence; convulsion; severe gastrointestinal ulceration including pneumatises cysteroides intestinalis, leading to peritonitis; sepsis and liver abscess; and pulmonary oedema.&nbsp;</p><p>&nbsp;</p><p>The risk of CNS toxicity increases if high dose cytarabine is given in combination with another CNS toxic treatment such as radiation therapy or in patients who have previously had CNS treatment as chemotherapy intrathecally. Rarely, neurological effects such as <strong>severe spinal cord toxicity even leading to necrotising encephalopathy, </strong>quadriplegia and paralysis and blindness have been reported with cytosine arabinoside and have been predominantly associated with intrathecal administration.&nbsp; Isolated cases have also been reported with high intravenous doses during combination chemotherapeutic regimens (see section 4.8).</p><p>&nbsp;</p><p>Delayed progressive ascending paralysis resulting in death has been reported in children with AML following intravenous cytarabine at conventional doses in combination with other drugs.</p><p>&nbsp;</p><p>Cytarabine has been shown to be mutagenic and carcinogenic in animals. The possibility of a similar effect should be borne in mind when designing the long-term management of the patient.</p><p>&nbsp;</p><p>Cytarabine should only be used under the constant supervision by physicians experienced in therapy with cytotoxic agents.&nbsp; Hyperuricemia secondary to rapid lysis of neoplastic cells may occur in patients receiving cytarabine; serum uric acid concentrations should be monitored. The physician should be prepared to use such supportive and pharmacological measures as may be necessary to control this problem.</p><p>&nbsp;</p><p>Periodic determinations of renal and hepatic functions and bone marrow should also be performed and the drug should be used with caution in patients with impaired hepatic function.</p><p>&nbsp;</p><p>However, dosage reduction does not appear to be necessary in patients with impaired renal function.&nbsp; The human liver apparently detoxifies a substantial fraction of the administered dose.&nbsp; The drug should be used with caution and at a reduced dose when liver function is poor.&nbsp; Frequent platelet and leucocyte counts are mandatory.&nbsp;</p><p>&nbsp;</p><p>Therapy should be suspended or modified when drug-induced bone marrow depression results in a platelet count of less than 50,000 or a polymorph nuclear count of under 1000 per mm<sup>3</sup>.&nbsp; Counts may continue to fall after the therapy has been discontinued and may reach lowest values after five to seven days.&nbsp; Therapy may be restarted when the bone marrow appears to be recovering on successive bone marrow studies.&nbsp; Therapy should not wait until the normal blood values are obtained to be re-initiated. If treatment is not resumed before blood values return to normal, the disease can get out of control.</p><p>&nbsp;</p><p>When intravenous doses are given quickly, patients may become nauseated and may vomit for several hours afterwards.&nbsp; The problem tends to be less severe when infused.</p><p>&nbsp;</p><p>Abdominal tenderness (peritonitis) and guaiac positive colitis, with concurrent neutropenia and thrombocytopenia, have been reported in patients treated with conventional doses of cytarabine in combination with other drugs. Patients have responded to non-operative medical management.</p><p>&nbsp;</p><p>Concurrent granulocyte-transfusion should be avoided as severe respiratory insufficiency has been reported.</p><p>&nbsp;</p><p><em>Immunosuppressant effects/Increased susceptibility to infections </em></p><p>Administration of live or live-attenuated vaccines in patients immunocompromised by chemotherapeutic agents including cytarabine, may result in serious or fatal infections. Vaccination with a live vaccine should be avoided in patients receiving cytarabine. Killed or inactivated vaccines may be administered; however, the response to such vaccines may be diminished.</p><p>&nbsp;</p><p><em>High dose therapy </em></p><p>Peripheral motor and sensory neuropathies after consolidation with high doses of cytarabine, daunorubicin, and asparaginase have occurred in adult patients with acute non lymphocytic leukaemia.</p><p>&nbsp;</p><p>Patients treated with high doses of cytarabine should be observed for neuropathy since dose adjustments may be needed to avoid irreversible neurologic disorders.</p><p>&nbsp;</p><p>Severe and sometimes fatal pulmonary toxicity, adult respiratory distress syndrome, and pulmonary edema have occurred following high dose schedules with cytarabine therapy. Cases of cardiomyopathy with subsequent death have been reported following experimental high dose therapy with cytarabine in combination with cyclophosphamide when used for bone marrow transplant preparation.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The safety of the drug has not been established in infants.</p><p>&nbsp;</p><p><u>Excipient information</u></p><p>Cytarabine 100 mg/ml Injection contains less than 1 mmol sodium (23 mg) in each vial, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Cardiac Glycosides</u></p><p>&nbsp;</p><p>GI absorption of oral digoxin tablets may be substantially reduced in patients receiving combination chemotherapy regimens (including regimens containing cytarabine), possibly as a result of temporary damage to intestinal mucosa caused by the cytotoxic agents.&nbsp; Reversible decreases in steady-state plasma digoxin concentrations and renal glycoside excretion were observed in patients receiving beta-acetyl digoxin and chemotherapy regimens containing cyclophosphamide, vincristine and prednisone with or without cytarabine or procarbazine. Limited data suggest that the extent of GI absorption of digitoxin is not substantially affected by concomitant administration of combination chemotherapy regimens known to decrease absorption of digoxin. Steady-state plasma digitoxin concentrations did not appear to change. Therefore, monitoring of plasma digoxin levels may be indicated in patients receiving similar combination chemotherapy regimens. The utilization of digitoxin for such patients may be considered as an alternative.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Anti-Infective Agents</u></p><p>&nbsp;</p><p>One <em>in vitro</em> study indicates that cytarabine may antagonise the activity of gentamicin against <em>Klebsiella pneumoniae</em>.&nbsp; In patients on cytarabine being treated with gentamicin for a <em>K.pneumoniae</em> infection, a lack of a prompt therapeutic response may indicate the need for re-evaluation of antibacterial therapy.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>5-Fluorocytosine: </u></p><p>5-Fluorocytosine should not be administered with cytarabine as the therapeutic efficacy of 5-Fluorocytosine has been shown to be abolished during such therapy.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Immunosuppressive Agents</u></p><p>&nbsp;</p><p>Due to the immunosuppressive action of cytarabine, viral, bacterial, fungal, parasitic, or saprophytic infections, in any location in the body, may be associated with the use of cytarabine alone or in combination with other immunosuppressive agents following immunosuppressant doses that affect cellular or humoral immunity. These infections may be mild, but can be severe and at times fatal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p><strong>&nbsp;</strong></p><p>Cytarabine is teratogenic in some animal species.&nbsp; It should not be used in pregnant women (especially during the first trimester) or in those who may become pregnant, unless the possible benefits outweigh the potential risks.&nbsp; Women who are, or who may become, pregnant during treatment with cytarabine should be informed of the risks.</p><p>&nbsp;</p><p>Men and women have to use effective contraception during and up to 6 months after treatment.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Breast-Feeding</u></p><p>&nbsp;</p><p>It is not known if cytarabine or its metabolite is distributed into breast milk, and it should not be used in mothers who are breastfeeding.</p><p>&nbsp;</p><p><u>Fertility </u></p><p>&nbsp;</p><p>Fertility studies to assess the reproductive toxicity of cytarabine have not been conducted. Gonadal suppression, resulting in amenorrhea or azoospermia, may occur in patients taking cytarabine therapy, especially in combination with alkylating agents. In general, these effects appear to be related to dose and length of therapy and may be irreversible. Given that cytarabine has a mutagenic potential which could induce chromosomal damage in the human spermatozoa, males undergoing cytarabine treatment and their partner should be advised to use a reliable contraceptive method.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No documented effect on ability to drive or operate machinery.</p><p>&nbsp;</p><p>Nevertheless, patients receiving chemotherapy may have an impaired ability to drive or operate machinery and should be warned of the possibility and advised to avoid such tasks if so affected.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following adverse events have been reported in association with cytarabine therapy. Frequencies are defined using the following convention:</p><p>Very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), not known (cannot be estimated from the available data)</p><p>&nbsp;</p><p>Undesirable effects from cytarabine are dose-dependent. Most common are gastrointestinal undesirable effects. Cytarabine is toxic to the bone marrow, and causes haematological undesirable effects.</p><p>&nbsp;</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Infections </em>and infestations </strong></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><em>Uncommon:</em><strong> </strong>Sepsis (immunosuppression)</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;<strong><em>Neoplasms benign, malignant and unspecified (including cysts and polyps)</em></strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;<em>Uncommon:</em> Lentigo</p><p><strong>&nbsp;</strong></p><p><strong><em>Blood and lymphatic system disorders:</em></strong></p><p><em>Common:</em> Anaemia, megaloblastosis, leukopenia, thrombocytopenia</p><p><em>Not known: Reticulocytopenia</em></p><p>&nbsp;</p><p>These appear to be more evident after high doses and continuous infusions; the severity depends on the dose of the drug and schedule of administration.</p><p>&nbsp;</p><p><strong><em>Gastrointestinal disorders </em></strong></p><p><em>Common: </em>Dysphagia, abdominal pain, nausea, vomiting, diarrhoea, oral/anal inflammation or ulceration</p><p><em>Uncommon:</em><em> </em>Oesophagitis, oesophageal ulceration, pneumatosis cystoides intestinalis, necrotising colitis, peritonitis</p><p><em>Not known: </em>Gastrointestinal haemorrhage, pancreatitis</p><p>&nbsp;</p><p>Nausea and vomiting occur and are generally more frequent following rapid IV administration than with continuous IV infusion of the drug.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><em>Skin and subcutaneous tissue disorders </em></strong></p><p><em>Common: </em>Reversible undesirable effects to the skin, such as erythema, bullous dermatitis, urticaria, vasculitis, alopecia</p><p><em>Uncommon:</em> skin ulceration, pruritus, burning pain of palms and soles</p><p><em>Very rare: </em>Neutrophilic eccrine hidradenitis</p><p>&nbsp;</p><p><em>Not known: </em>Rash, freckling, skin bleeding</p><p><strong>&nbsp;</strong></p><p><strong><em>Renal and urinary disorders </em></strong></p><p><em>Common: </em>Renal impairment, urinary retention</p><p><em>Not known: </em>Renal dysfunction</p><p>&nbsp;</p><p><strong><em>General disorders and administration site conditions </em></strong></p><p><em>Common: </em>Fever, thrombophlebitis at the site of injection</p><p><em>Uncommon: </em>Cellulitis at the injection site</p><p><em>Not known: </em>Chest pain, irritation or sepsis at the injection site, mucosal bleeding</p><p>&nbsp;</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Cardiac disorders </em></strong></p><p><em>Uncommon: </em>Pericarditis</p><p><em>Very rare: </em>Arrhythmia</p><p><em>Not Known:</em> Sinus bradycardia</p><p><strong>&nbsp;</strong></p><p><strong><em>Hepatobiliary disorders </em></strong></p><p><em>Common: </em>Reversible effects on the liver with increased enzyme levels</p><p><em>Not known: </em>Hepatic dysfunction and jaundice</p><p><strong>&nbsp;</strong></p><p><strong><em>Metabolism and nutrition disorders </em></strong></p><p><em>Common: </em>Anorexia, hyperuricemia</p><p>One case of anaphylaxis that resulted in cardiopulmonary arrest and necessitated resuscitation has been reported (see section 4.4 Special warnings and precautions for use).</p><p>&nbsp;</p><p><strong><em>Nervous system disorders </em></strong></p><p><em>Common: </em>At high doses cerebellar or cerebral influence with deterioration of the level of consciousness, dysarthria, nystagmus</p><p><em>Uncommon: </em>Headache, peripheral neuropathy, paraplegia at intrathecal administration</p><p><em>Not known: </em>Dizziness, neuritis or neural toxicity and pain, neurotoxicity rash</p><p><strong>&nbsp;</strong></p><p><strong><em>Eye disorders </em></strong></p><p><em>Common: </em>Reversible haemorrhagic conjunctivitis (photophobia, burning, visual disturbance, increased lacrimation), keratitis</p><p><em>Not known: </em>Conjunctivitis<br />&nbsp;</p><p><strong><em>Respiratory, thoracic and mediastinal disorders </em></strong></p><p><em>Uncommon: </em>Pneumonia, dyspnoea, sore throat.<br />&nbsp;</p><p><strong><em>Musculoskeletal and connective tissue disorders </em></strong></p><p><em>Uncommon: </em>Myalgia, joint pain.</p><p><strong>&nbsp;</strong></p><p><strong>A cytarabine syndrome (immunoallergic effect)</strong> is characterised by fever, myalgia, bone pain, occasionally chest pain, exanthema, maculopapular rash, conjunctivitis, nausea and malaise. It usually occurs 6-12 hours after administration. Corticosteroids have been shown to be beneficial in treating or preventing this syndrome. If the symptoms of the syndrome are serious enough to warrant treatment, corticosteroids should be contemplated. If treatment is effective, therapy with cytarabine may be continued.</p><p><strong>&nbsp;</strong></p><p><strong>Adverse effects due to high dose cytarabine treatment, other than those seen with conventional doses include:</strong><br />&nbsp;</p><p><strong>Blood and lymphatic system disorders </strong></p><p>Hematological toxicity has been seen as profound pancytopenia which may last 15-25 days along with more severe bone marrow aplasia than that observed at conventional doses.</p><p>&nbsp;</p><p><strong>Nervous system disorders </strong></p><p>After treatment with high doses of cytarabine, symptoms of cerebral or cerebellar influence like personality changes, affected alertness, dysarthria, ataxia, tremor, nystagmus, headache, confusion, somnolence, dizziness, coma, convulsions, etc. appear in 8-37 % of treated patients. The incidence in elderly (&gt;55 years) may be even higher. Other predisposing factors are impaired liver and renal function, previous CNS treatment (e.g., radiotherapy) and alcohol abuse. CNS disturbances are in the most cases reversible.</p><p>&nbsp;</p><p>The risk of CNS toxicity increases if the cytarabine treatment -given as high dose i.v.- is combined with another CNS toxic treatment such as radiation therapy or high dose of a cytotoxic agent.</p><p>&nbsp;</p><p><strong>Eye disorders </strong></p><p>Reversible corneal lesion and haemorrhagic conjunctivitis have been described. These phenomena can be prevented or decreased by installation of corticosteroid eye drops.</p><p>&nbsp;</p><p><strong>Gastrointestinal disorders </strong></p><p>Especially in treatment with high doses of cytarabine, more severe reactions may appear in addition to common symptoms. Intestinal perforation or necrosis with ileus and peritonitis have been reported. Pancreatitis has also been observed after high-dose therapy.</p><p><strong>&nbsp;</strong></p><p><strong>Hepatobiliary disorders </strong></p><p>Liver abscesses, hepatomegaly and Budd-Chiari-syndrome (hepatic venous thrombosis) have been observed after high-dose therapy.</p><p>&nbsp;</p><p><strong>Respiratory, thoracic and mediastinal disorders </strong></p><p>Clinical signs as present in pulmonary oedema/ARDS may develop, particularly in high-dose therapy. The reaction is probably caused by an alveolar capillary injury. It is difficult to make an assessment of frequencies (stated as 10-26 % in different publications), since the patients usually have been in relapse where other factors may contribute to this reaction.</p><p>&nbsp;</p><p><strong>Reproductive system and breast disorders </strong></p><p>Amenorrhoea and azoospermia</p><p>&nbsp;</p><p><strong>Others </strong></p><p>Following cytarabine therapy, cardiomyopathy and rhabdomyolysis have been reported.</p><p>&nbsp;</p><p>The gastrointestinal undesirable effects are reduced if cytarabine is administered as infusion. Local glucocorticoids are recommended as prophylaxis of haemorrhagic conjunctivitis.</p><p><strong>&nbsp;</strong></p><p>One case of anaphylaxis that resulted in cardiopulmonary arrest and necessitated resuscitation has been reported (see section 4.4).</p><p><strong>&nbsp;</strong></p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after <u>marketing</u> authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions <u>according to their local requirements. </u></p><p>&nbsp;</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>To Report side effects</strong></p><p>&nbsp;</p><ul><li>Saudi Arabia</li></ul><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance (NPC)</p><ul><li>SFDA Call center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa</li></ul><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Other GCC States:</strong></p><p> Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no specific antidote for cytarabine overdose. Cessation of therapy followed by management of ensuing bone marrow depression including whole blood or platelet transfusion and antibiotics as required.</p><p>&nbsp;</p><p>Twelve doses of 4.5 g/m<sup>2</sup> by IV infusion over one hour every 12 hours induces irreversible and fatal central nervous system toxicity.</p><p>&nbsp;</p><p>Cytarabine may be removed by haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Pyrimidine analogues, ATC code: L01BC01</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p><strong>&nbsp;</strong></p><p>Cytarabine (ARA-C) is metabolised <em>in vivo</em> to ARA-CTP phosphorylated compound.&nbsp; This competitively inhibits DNA polymerase and may also inhibit certain acid kinase enzymes.&nbsp; Primarily the drug acts as a false nucleoside and competes for enzymes involved in the conversion of cytidine nucleotide to deoxycytidine nucleotide and also incorporation into the DNA.</p><p>&nbsp;</p><p>Cytarabine has no effect on non-proliferating cells nor on proliferating cells unless in the S phase.&nbsp; It is a cell cycle specific antineoplastic drug.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Oral administration is ineffective due to rapid deamination in the gut.&nbsp; Cytidine deaminase is concentrated in the liver and intravenous doses show biphasic elimination with half-lives of approximately 10 minutes and 1-3 hours.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>After 24 hours 80% of a dose has been eliminated either as the inactive metabolite or as the unchanged cytarabine, mostly in urine but some in bile.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>CSF levels of 50% of plasma levels are achieved with intravenous infusion.&nbsp; Intrathecal dosing results in slower elimination (T<sub>1/2</sub> 2-11 hours).</p><p>&nbsp;</p><p>Cytarabine is rapidly and widely distributed into tissues, crosses the blood brain barrier and also the placenta.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Oral administration is ineffective due to rapid deamination in the gut.&nbsp; Cytidine deaminase is concentrated in the liver and intravenous doses show biphasic elimination with half-lives of approximately 10 minutes and 1-3 hours.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>After 24 hours 80% of a dose has been eliminated either as the inactive metabolite or as the unchanged cytarabine, mostly in urine but some in bile.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>CSF levels of 50% of plasma levels are achieved with intravenous infusion.&nbsp; Intrathecal dosing results in slower elimination (T<sub>1/2</sub> 2-11 hours).</p><p>&nbsp;</p><p>Cytarabine is rapidly and widely distributed into tissues, crosses the blood brain barrier and also the placenta.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Water for Injections</p><p>Hydrochloric Acid (for pH adjustment)</p><p>Sodium Hydroxide (for pH adjustment)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Solutions of cytarabine have been reported to be incompatible with various drugs, i.e. carbenicillin sodium, cephalothin sodium, fluorouracil, gentamicin sulphate, heparin sodium, hydrocortisone sodium succinate, insulin-regular, methylprednisolone sodium succinate, nafacillin sodium, oxacillin sodium, penicillin G sodium.&nbsp; However, the incompatibility depends on several factors (e.g. concentrations of the drug, specific diluents used, resulting pH, temperature).&nbsp; Specialised references should be consulted for specific compatibility information.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Do not use Cytarabine after the expiry date which is stated on the carton label after EXP:. The expiry date refers to the last day of that month.

Before use: 18 months

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not refrigerate or freeze.</p><p>&nbsp;</p><p>Do not store above 25&deg;C.&nbsp; Keep container in the outer carton in order to protect from light.</p><p>Discard any unused contents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clear Type I glass Onco-Tain<sup>&reg;</sup> vial with rubber stopper</p><p>&nbsp;</p><p>Pack sizes 1&rsquo;s and 5&rsquo;s.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prior to use, vials of Cytarabine 100mg/ml Injection must be warmed to 55&deg;C, for 30 minutes, with adequate shaking, and allowed to cool to room temperature.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hospira UK Limited 
	Horizon
	Honey Lane
	Hurley
	Maidenhead
	SL6 6RJ
	United Kingdom

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                April 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>